Related Experiment Video
Updated: May 17, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Brain metastasis: opportunity for drug development?
Matthias Preusser1, Anna S Berghoff, Dirk Schadendorf
1Department of Medicine I and Comprehensive Cancer Center CNS Unit, Medical University of Vienna, Vienna, Austria. Matthias.preusser@meduniwien.ac.at
Purpose Of Review:
Brain metastases are a common clinical problem, and only limited treatment options exist. We review recent advances in medical brain metastasis research with a focus on the most common tumor types associated with secondary brain colonization: melanoma, breast cancer and lung cancer. We speculate on opportunities for drug development in patients with brain metastases, both as a treatment of established disease and as an adjuvant and prophylactic strategy.
Recent Findings:
BRAF inhibitors and the immunomodulatory anticytotoxic T-lymphocyte-associated antigen 4 antibody ipilimumab have shown clinically meaningful activity in melanoma patients with brain metastases. In breast cancer, current studies on drug treatment of brain metastases are mainly focusing on human epidermal growth factor receptor 2 targeting agents such as lapatinib. Emerging data seem to implicate a potential role of targeted agents including antiangiogenic compounds, pazopanib, and epithelial growth factor receptor inhibitors for prevention of brain metastasis formation in breast cancer or nonsmall cell lung cancer.
Summary:
Novel drugs are beginning to enter clinical practice for selected patients with brain metastases. The promising findings from recent studies may fuel more research on brain metastases and their optimal drug treatment.
Insights
Novel treatments show promise for brain metastases in melanoma, breast, and lung cancers. Research is advancing drug development for established disease and prevention strategies.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- Brain metastases represent a significant clinical challenge with limited therapeutic options.
- Secondary brain colonization is common in melanoma, breast, and lung cancers.
Purpose of the Study:
- To review recent advancements in medical research for brain metastases.
- To explore drug development opportunities for treating and preventing brain metastases.
Main Methods:
- Review of recent clinical studies and emerging data.
- Focus on melanoma, breast cancer, and lung cancer brain metastases.
Main Results:
- BRAF inhibitors and ipilimumab show activity in melanoma brain metastases.
- HER2-targeting agents like lapatinib are studied for breast cancer brain metastases.
- Targeted agents show potential for preventing brain metastases in breast and lung cancers.
Conclusions:
- New drugs are becoming available for specific brain metastasis patients.
- Promising findings are expected to stimulate further research in brain metastasis treatment.
Related Concept Videos
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...